This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alexander, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alexander, D.
Related Collections
Right arrow Premature & Newborn
PEDIATRICS Vol. 113 No. 1 January 2004, pp. 135

COMMENTARY

A Method for Interdicting the Development of Severe Jaundice in Newborns by Inhibiting the Production of Bilirubin

Duane Alexander, MD

National Institute of Child Health and Human Development
National Institutes of Health
Department of Health and Human Services
Bethesda, MD 20892-2425

The first 20% of the full text of this article appears below.

Every now and then, in a pharmaceutical world dominated by agents that are "me-toos" or "variations on a theme," there appears a truly new molecular entity that offers an entirely new approach to treating a disorder that previously had only partially effective therapies or, sometimes, no effective therapy at all. The article by Attallah Kappas1 in this issue describes such a potential advance: tin-mesoporphyrin. This truly new entity was developed specifically by Kappas and his colleagues to block the action of heme oxygenase in converting hemoglobin to bilirubin. By shutting off the production of bilirubin at its source rather than removing it by exchange transfusion or phototherapy after it is formed, this agent has the potential to revolutionize management of jaundice from any cause just as Rh immune globulin did for preventing Rh hemolytic disease of the newborn when introduced in the 1960s.

What is remarkable (and lamentable) is that . . . [Full Text of this Article]

Address correspondence to Duane Alexander, MD, National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, 31 Center Dr, Room 2A03, MSC 2425, Bethesda, MD 20892-2425. E-mail: da43w@nih.gov




This article has been cited by other articles:


Home page
 Exp. Biol. Med.Home page
Z.-W. Xia, C.-E Li, Y.-X. Jin, Y. Shi, L.-Q. Xu, W.-W. Zhong, Y.-Z. Li, S.-C. Yu, and Z.-L. Zhang
Reduction of Bilirubin by Targeting Human Heme Oxygenase-1 Through siRNA
Experimental Biology and Medicine, April 1, 2007; 232(4): 495 - 502.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
G. R. Gourley, Z. Li, B. L. Kreamer, and M. R. Kosorok
A Controlled, Randomized, Double-Blind Trial of Prophylaxis Against Jaundice Among Breastfed Newborns
Pediatrics, August 1, 2005; 116(2): 385 - 391.
[Abstract] [Full Text] [PDF]